1.Pre-hospital Korean Triage and Acuity Scale: the results of first and second pilot projects
Changshin KANG ; Han Joo CHOI ; Sang-Il KIM ; Yong Oh KIM ; Jung-Youn KIM ; Jungho KIM ; Hyun NOH ; Hyun Ho RYU ; Jung Hee WEE ; Gyuuk HWANG ; Ki Jeong HONG ; Jae Yun AHN ; Chun Song YOUN ; Eunsil KO ; Minhee LEE ; Sung-keun KO ; Tae Young LEE ; Eul Hee ROH ; Joonbum PARK
Journal of the Korean Society of Emergency Medicine 2024;35(1):6-15
		                        		
		                        			
		                        			 While the Korean Triage and Acuity Scale (KTAS) was introduced in 2016 as a tool to identify patients at risk of catastrophic events, including death in the ED, the triage system for the pre-hospital stage still lacks evidence. The pre-hospital stage is characterized by time-sensitive and complex scenarios, where rapid and accurate decision-making is paramount to optimize patient outcomes. Despite the vital role of pre-hospital care providers, the invalidated and subjective current triage system consisting of 4-stages is still used at the pre-hospital stage, and hence, it needs to be modified to be more objective, standardized, and reliable. To improve the Korean emergency medical system, the pre-hospital KTAS (Pre-KTAS) was developed in 2020, and then two pilot projects were conducted in 2022 and 2023. This paper not only reveals the results of the first and second pilot projects for Pre-KTAS but also highlights the potential benefits of using this newly developed triage tool in the pre-hospital setting. Furthermore, this paper suggests ways to improve the emergency medical system (EMS) in Korea by improving patient safety, resource allocation, and overall emergency response efficiency. 
		                        		
		                        		
		                        		
		                        	
2.Added Value of Contrast Leakage Information over the CBV Value of DSC Perfusion MRI to Differentiate between Pseudoprogression and True Progression after Concurrent Chemoradiotherapy in Glioblastoma Patients
Elena PAK ; Seung Hong CHOI ; Chul-Kee PARK ; Tae Min KIM ; Sung-Hye PARK ; Jae-Kyung WON ; Joo Ho LEE ; Soon-Tae LEE ; Inpyeong HWANG ; Roh-Eul YOO ; Koung Mi KANG ; Tae Jin YUN
Investigative Magnetic Resonance Imaging 2022;26(1):10-19
		                        		
		                        			 Purpose:
		                        			To evaluate whether the added value of contrast leakage information from dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) is a better prognostic imaging biomarker than the cerebral blood volume (CBV) value in distinguishing true progression from pseudoprogression in glioblastoma patients. 
		                        		
		                        			Materials and Methods:
		                        			Forty-nine glioblastoma patients who had undergone MRI after concurrent chemoradiotherapy with temozolomide were enrolled in this retrospective study. Twenty features were extracted from the normalized relative CBV (nCBV) and extraction fraction (EF) map of the contrast-enhancing region in each patient. After univariable analysis, we used multivariable stepwise logistic regression analysis to identify significant predictors for differentiating between pseudoprogression and true progression. Receiver operating characteristic (ROC) analysis was employed to determine the best cutoff values for the nCBV and EF features. Finally, leave-one-out cross-validation was used to validate the best predictor in differentiating between true progression and pseudoprogression. 
		                        		
		                        			Results:
		                        			Multivariable stepwise logistic regression analysis showed that MGMT (O 6 -methylguanine-DNA methyltransferase) and EF max were independent differentiating variables (P = 0.004 and P = 0.02, respectively). ROC analysis yielded the best cutoff value of 95.75 for the EF max value for differentiating the two groups (sensitivity, 61%; specificity, 84.6%; AUC, 0.681 ± 0.08; 95% CI, 0.524-0.837; P = 0.03). In the leave-one-out cross-validation of the EF max value, the cross-validated values for predicting true progression and pseudoprogression accuracies were 69.4% and 71.4%,respectively. 
		                        		
		                        			Conclusion
		                        			We demonstrated that contrast leakage information parameter from DSC MRI showed significance in differentiating true progression from pseudoprogression in glioblastoma patients. 
		                        		
		                        		
		                        		
		                        	
3.Application of T1 Map Information Based on Synthetic MRI for Dynamic Contrast-Enhanced Imaging:A Comparison Study with the Fixed Baseline T1 Value Method
Dong Jae SHIN ; Seung Hong CHOI ; Roh-Eul YOO ; Koung Mi KANG ; Tae Jin YUN ; Ji-Hoon KIM ; Chul-Ho SOHN ; Sang Won JO ; Eun Jung LEE
Korean Journal of Radiology 2021;22(8):1352-1368
		                        		
		                        			Objective:
		                        			For an accurate dynamic contrast-enhanced (DCE) MRI analysis, exact baseline T1 mapping is critical. The purpose of this study was to compare the pharmacokinetic parameters of DCE MRI using synthetic MRI with those using fixed baseline T1 values. 
		                        		
		                        			Materials and Methods:
		                        			This retrospective study included 102 patients who underwent both DCE and synthetic brain MRI. Two methods were set for the baseline T1: one using the fixed value and the other using the T1 map from synthetic MRI. The volume transfer constant (Ktrans ), volume of the vascular plasma space (vp), and the volume of the extravascular extracellular space (ve) were compared between the two methods. The interclass correlation coefficients and the Bland-Altman method were used to assess the reliability. 
		                        		
		                        			Results:
		                        			In normal-appearing frontal white matter (WM), the mean values of Ktrans , ve, and vp were significantly higher in the fixed value method than in the T1 map method. In the normal-appearing occipital WM, the mean values of ve and vp were significantly higher in the fixed value method. In the putamen and head of the caudate nucleus, the mean values of Ktrans , ve, and vp were significantly lower in the fixed value method. In addition, the T1 map method showed comparable interobserver agreements with the fixed baseline T1 value method. 
		                        		
		                        			Conclusion
		                        			The T1 map method using synthetic MRI may be useful for reflecting individual differences and reliable measurements in clinical applications of DCE MRI.
		                        		
		                        		
		                        		
		                        	
4.Application of T1 Map Information Based on Synthetic MRI for Dynamic Contrast-Enhanced Imaging:A Comparison Study with the Fixed Baseline T1 Value Method
Dong Jae SHIN ; Seung Hong CHOI ; Roh-Eul YOO ; Koung Mi KANG ; Tae Jin YUN ; Ji-Hoon KIM ; Chul-Ho SOHN ; Sang Won JO ; Eun Jung LEE
Korean Journal of Radiology 2021;22(8):1352-1368
		                        		
		                        			Objective:
		                        			For an accurate dynamic contrast-enhanced (DCE) MRI analysis, exact baseline T1 mapping is critical. The purpose of this study was to compare the pharmacokinetic parameters of DCE MRI using synthetic MRI with those using fixed baseline T1 values. 
		                        		
		                        			Materials and Methods:
		                        			This retrospective study included 102 patients who underwent both DCE and synthetic brain MRI. Two methods were set for the baseline T1: one using the fixed value and the other using the T1 map from synthetic MRI. The volume transfer constant (Ktrans ), volume of the vascular plasma space (vp), and the volume of the extravascular extracellular space (ve) were compared between the two methods. The interclass correlation coefficients and the Bland-Altman method were used to assess the reliability. 
		                        		
		                        			Results:
		                        			In normal-appearing frontal white matter (WM), the mean values of Ktrans , ve, and vp were significantly higher in the fixed value method than in the T1 map method. In the normal-appearing occipital WM, the mean values of ve and vp were significantly higher in the fixed value method. In the putamen and head of the caudate nucleus, the mean values of Ktrans , ve, and vp were significantly lower in the fixed value method. In addition, the T1 map method showed comparable interobserver agreements with the fixed baseline T1 value method. 
		                        		
		                        			Conclusion
		                        			The T1 map method using synthetic MRI may be useful for reflecting individual differences and reliable measurements in clinical applications of DCE MRI.
		                        		
		                        		
		                        		
		                        	
5.Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas
Eun Kyoung HONG ; Seung Hong CHOI ; Dong Jae SHIN ; Sang Won JO ; Roh-Eul YOO ; Koung Mi KANG ; Tae Jin YUN ; Ji-hoon KIM ; Chul-Ho SOHN ; Sung-Hye PARK ; Jae-Kyoung WON ; Tae Min KIM ; Chul-Kee PARK ; Il Han KIM ; Soon-Tae LEE
Korean Journal of Radiology 2021;22(2):233-242
		                        		
		                        			 Objective:
		                        			To evaluate the association of MRI features with the major genomic profiles and prognosis of World Health Organization grade III (G3) gliomas compared with those of glioblastomas (GBMs). 
		                        		
		                        			Materials and Methods:
		                        			We enrolled 76 G3 glioma and 155 GBM patients with pathologically confirmed disease who had pretreatment brain MRI and major genetic information of tumors. Qualitative and quantitative imaging features, including volumetrics and histogram parameters, such as normalized cerebral blood volume (nCBV), cerebral blood flow (nCBF), and apparent diffusion coefficient (nADC) were evaluated. The G3 gliomas were divided into three groups for the analysis: with this isocitrate dehydrogenase (IDH)-mutation, IDH mutation and a chromosome arm 1p/19q-codeleted (IDHmut1p/19qdel), IDH mutation, 1p/19q-nondeleted (IDHmut1p/19qnondel), and IDH wildtype (IDHwt). A prediction model for the genetic profiles of G3 gliomas was developed and validated on a separate cohort. Both the quantitative and qualitative imaging parameters and progression-free survival (PFS) of G3 gliomas were compared and survival analysis was performed. Moreover, the imaging parameters and PFS between IDHwt G3 gliomas and GBMs were compared. 
		                        		
		                        			Results:
		                        			IDHmut G3 gliomas showed a larger volume (p = 0.017), lower nCBF (p = 0.048), and higher nADC (p = 0.007) than IDHwt. Between the IDHmut tumors, IDHmut1p/19qdel G3 gliomas had higher nCBV (p = 0.024) and lower nADC (p = 0.002) than IDHmut1p/19qnondel G3 gliomas. Moreover, IDHmut1p/19qdel tumors had the best prognosis and IDHwt tumors had the worst prognosis among G3 gliomas (p < 0.001). PFS was significantly associated with the 95th percentile values of nCBV and nCBF in G3 gliomas. There was no significant difference in neither PFS nor imaging features between IDHwt G3 gliomas and IDHwt GBMs.  
		                        		
		                        			Conclusion
		                        			We found significant differences in MRI features, including volumetrics, CBV, and ADC, in G3 gliomas, according to IDH mutation and 1p/19q codeletion status, which can be utilized for the prediction of genomic profiles and the prognosis of G3 glioma patients. The MRI signatures and prognosis of IDHwt G3 gliomas tend to follow those of IDHwt GBMs. 
		                        		
		                        		
		                        		
		                        	
6.Corrigendum: Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro).
Jae Hoon MOON ; Ji Hoon KIM ; Eun Kyung LEE ; Kyu Eun LEE ; Sung Hye KONG ; Yeo Koon KIM ; Woo Jin JEONG ; Chang Yoon LEE ; Roh Eul YOO ; Yul HWANGBO ; Young Shin SONG ; Min Joo KIM ; Sun Wook CHO ; Su Jin KIM ; Eun Jae CHUNG ; June Young CHOI ; Chang Hwan RYU ; You Jin LEE ; Jeong Hun HAH ; Yuh Seog JUNG ; Junsun RYU ; Yunji HWANG ; Sue K PARK ; Ho Kyung SUNG ; Ka Hee YI ; Do Joon PARK ; Young Joo PARK
Endocrinology and Metabolism 2018;33(3):427-427
		                        		
		                        			
		                        			No abstract available.
		                        		
		                        		
		                        		
		                        	
7.Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro).
Jae Hoon MOON ; Ji hoon KIM ; Eun Kyung LEE ; Kyu Eun LEE ; Sung Hye KONG ; Yeo Koon KIM ; Woo jin JUNG ; Chang Yoon LEE ; Roh Eul YOO ; Yul HWANGBO ; Young Shin SONG ; Min Joo KIM ; Sun Wook CHO ; Su jin KIM ; Eun Jae JUNG ; June Young CHOI ; Chang Hwan RYU ; You Jin LEE ; Jeong Hun HAH ; Yuh Seog JUNG ; Junsun RYU ; Yunji HWANG ; Sue K PARK ; Ho Kyung SUNG ; Ka Hee YI ; Do Joon PARK ; Young Joo PARK
Endocrinology and Metabolism 2018;33(2):278-286
		                        		
		                        			
		                        			BACKGROUND: The ongoing Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) aims to observe the natural course of papillary thyroid microcarcinoma (PTMC), develop a protocol for active surveillance (AS), and compare the long-term prognosis, quality of life, and medical costs between the AS and immediate surgery groups. METHODS: This multicenter prospective cohort study of PTMC started in June 2016. The inclusion criteria were suspicious of malignancy or malignancy based on fine needle aspiration or core needle biopsy, age of ≥18 years, and a maximum diameter of ≤1 cm. If there was no major organ involvement, no lymph node/distant metastasis, and no variants with poor prognosis, the patients were explained of the pros and cons of immediate surgery and AS before selecting AS or immediate surgery. Follow-up visits (physical examination, ultrasonography, thyroid function, and questionnaires) are scheduled every 6 months during the first 2 years, and then every 1 year thereafter. Progression was defined as a maximum diameter increase of ≥3, ≥2 mm in two dimensions, suspected organ involvement, or lymph node/distant metastasis. RESULTS: Among 439 enrolled patients, 290 patients (66.1%) chose AS and 149 patients (33.9%) chose immediate surgery. The median follow-up was 6.7 months (range, 0.2 to 11.9). The immediate surgery group had a larger maximum tumor diameter, compared to the AS group (7.1±1.9 mm vs. 6.6±2.0 mm, respectively; P=0.014). CONCLUSION: The results will be useful for developing an appropriate PTMC treatment policy based on its natural course and risk factors for progression.
		                        		
		                        		
		                        		
		                        			Biopsy, Fine-Needle
		                        			;
		                        		
		                        			Biopsy, Large-Core Needle
		                        			;
		                        		
		                        			Cohort Studies*
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Neoplasm Metastasis
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Prospective Studies*
		                        			;
		                        		
		                        			Quality of Life
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Thyroid Gland*
		                        			;
		                        		
		                        			Thyroid Neoplasms
		                        			;
		                        		
		                        			Ultrasonography
		                        			
		                        		
		                        	
8.GAB2 Amplification in Squamous Cell Lung Cancer of Non-Smokers.
Yu Rang PARK ; Soo Hyeon BAE ; Wonjun JI ; Eul Ju SEO ; Jae Cheol LEE ; Hyeong Ryul KIM ; Se Jin JANG ; Chang Min CHOI
Journal of Korean Medical Science 2017;32(11):1784-1791
		                        		
		                        			
		                        			Lung squamous cell cancer (SCC) is typically found in smokers and has a very low incidence in non-smokers, indicating differences in the tumor biology of lung SCC in smokers and non-smokers. However, the specific mutations that drive tumor growth in non-smokers have not been identified. To identify mutations in lung SCC of non-smokers, we performed a genetic analysis using arrays comparative genomic hybridization (ArrayCGH). We analyzed 19 patients with lung SCC who underwent surgical treatment between April 2005 and April 2015. Clinical characteristics were reviewed, and DNA was extracted from fresh frozen lung cancer specimens. All of copy number alterations from ArrayCGH were validated using The Cancer Genome Atlas (TCGA) copy number variation (CNV) data of lung SCC. We examined the frequency of copy number changes according to the smoking status (non-smoker [n = 8] or smoker [n = 11]). We identified 16 significantly altered regions from ArrayCGH data, three gain and four loss regions overlapped with the TCGA lung squamous cell carcinoma (LUSC) patients. Within these overlapped significant regions, we detected 15 genes that have been reported in the Cancer Gene census. We also found that the proto-oncogene GAB2 (11q14.1) was significantly amplified in non-smokers patients and vice versa in both ArrayCGH and TCGA data. Immunohistochemical analyses showed that GAB2 protein was relatively upregulated in non-smoker than smoker tissues (37.5% vs. 9.0%, P = 0.007). GAB2 amplification may have an important role in the development of lung SCC in non-smokers. GAB2 may represent a potential biomarker for lung SCC in non-smokers.
		                        		
		                        		
		                        		
		                        			Biology
		                        			;
		                        		
		                        			Carcinoma, Squamous Cell
		                        			;
		                        		
		                        			Censuses
		                        			;
		                        		
		                        			Comparative Genomic Hybridization
		                        			;
		                        		
		                        			DNA
		                        			;
		                        		
		                        			Epithelial Cells*
		                        			;
		                        		
		                        			Genes, Neoplasm
		                        			;
		                        		
		                        			Genome
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Lung Neoplasms*
		                        			;
		                        		
		                        			Lung*
		                        			;
		                        		
		                        			Neoplasms, Squamous Cell
		                        			;
		                        		
		                        			Proto-Oncogenes
		                        			;
		                        		
		                        			Smoke
		                        			;
		                        		
		                        			Smoking
		                        			
		                        		
		                        	
9.Control Efficacy of Streptomyces sp. A501 against Ginseng Damping-off and Its Antifungal Substance.
Nguyen VAN MINH ; E Eum WOO ; Gang Seon LEE ; Dae Won KI ; In Kyoung LEE ; Sang Yeob LEE ; Kyeonghun PARK ; Jaekyeong SONG ; Jae Eul CHOI ; Bong Sik YUN
Mycobiology 2017;45(1):44-47
		                        		
		                        			
		                        			Ginseng damping-off, caused by the fungal pathogens Rhizoctonia solani and Pythium sp., is a critical disease in ginseng seedling. In a continuing effort to find microorganisms with the potential of acting as a biocontrol agent against Rhizoctonia damping-off, we found that a Streptomyces sp. A501 showed significant antifungal activity against Rhizoctonia solani. In field experiment to test the efficacy of Streptomyces sp. A501 in controlling ginseng damping-off, the incidence of damping-off disease was meaningfully reduced when ginseng seeds were soaked in the culture broth of Streptomyces sp. A501 before sowing. To perform characterization of the antifungal compound, we isolated it from the culture broth of strain A501 through Diaion HP-20 and silica gel column chromatographies and preparative high-performance liquid chromatography. The structure of the antifungal compound was assigned as fungichromin by spectroscopic methods, mainly nuclear magnetic resonance and electrospray ionization-mass analysis.
		                        		
		                        		
		                        		
		                        			Chromatography
		                        			;
		                        		
		                        			Chromatography, Liquid
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Magnetic Resonance Spectroscopy
		                        			;
		                        		
		                        			Panax*
		                        			;
		                        		
		                        			Pythium
		                        			;
		                        		
		                        			Rhizoctonia
		                        			;
		                        		
		                        			Seedlings
		                        			;
		                        		
		                        			Silica Gel
		                        			;
		                        		
		                        			Streptomyces*
		                        			
		                        		
		                        	
10.Subacute Thyroiditis and Painless Thyroiditis: Clinical Characteristics of 221 Patients Diagnosed between 2009 and 2015.
Jung Ah CHOI ; Yong Hyun KIM ; Dong Hyun SHIN ; Jae Min LEE ; Jin Young HEO ; Hyun Mi KIM ; Won Il PARK ; Chul Young KIM ; In Hye LEE ; Ji Su KIM ; Go Eul KIM
International Journal of Thyroidology 2016;9(2):145-151
		                        		
		                        			
		                        			BACKGROUND AND OBJECTIVES: In the past, subacute thyroiditis causing thyrotoxicosis included both painful and painless subgroup, but it is representative for the painful subacute thyroiditis these days. So we evaluated the clinical and laboratory characteristics of subacute thyroiditis and compared with the painless (silent) thyroiditis, and identified predictive factors of permanent hypothyroidism and recurrence. MATERIALS AND METHODS: This was a retrospective case series study analyzing clinical data of 221 consecutive patients diagnosed between 2009 and 2015. Medical records were reviewed for diagnostic route, age distribution, laboratory data, clinical course and long-term follow up outcome. RESULTS: The mean age was 48 years; female v/s male ratio 3.4:1. Median disease duration was 110 days; mean peak free T4 level was 2.9 ng/dL. 56.7% of painless thyroiditis patients were diagnosed on health checkup or routine thyroid function test with symptoms not typically associated with thyrotoxicosis. Permanent hypothyroidism was not uncommon (11/221; 5.0%). Higher peak thyroid-stimulating hormone (TSH) was associated with permanent hypothyroidism in painless thyroiditis. Lower peak TSH was associated with recurrence rate in both subacute and painless thyroiditis. In painless thyroiditis, short duration of thyrotoxicosis phase was also associated with recurrence rate. CONCLUSION: Considerable numbers of painless thyroiditis without symptoms were diagnosed on health checkup. Higher peak TSH was associated with permanent hypothyroidism in painless thyroiditis. Recurrence rate was related with lower peak TSH in both groups.
		                        		
		                        		
		                        		
		                        			Age Distribution
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hypothyroidism
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Medical Records
		                        			;
		                        		
		                        			Postpartum Thyroiditis
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Thyroid Function Tests
		                        			;
		                        		
		                        			Thyroid Gland*
		                        			;
		                        		
		                        			Thyroiditis*
		                        			;
		                        		
		                        			Thyroiditis, Subacute*
		                        			;
		                        		
		                        			Thyrotoxicosis
		                        			;
		                        		
		                        			Thyrotropin
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail